| Under-the-radar company could be a game changer for depression
| | | Please find below a special message from our advertising sponsor, Cybin. Golden Opportunities is a free service that gives you valuable investment intelligence all year long at no charge, and advertisements allow us to continue sending these reports.
| |
| New Hope For Depression Sufferers
| |
Depression afflicts more than 264 million people globally, and yet Big Pharma’s drugs for depression — a huge $60 billion business — are only effective for some.
Now, clinical uses of psychedelics are gaining favor as a treatment for depression, PTSD and a host of other mental health diagnoses.
And under-the-radar company Cybin (NYSE: CYBN) appears to have an excellent chance of turning psychedelics’ promise into a big win for investors.
| | | |
It’s a potential cure for depression and other mental illness that has taken the market by surprise.
|
After spending 50 years on the FDA’s Schedule 1 list, psychedelic drugs like psilocybin (the active ingredient in magic mushrooms) are getting a fresh look as a treatment for depression, PTSD, OCD, addiction and more.
Administered in clinical settings, these drugs are showing real promise as an alternative to the $60 billion sector controlled by Big Pharma.
|
And with an Investigational New Drug in the approval pipeline and another set to enter Phase 1 trials, Cybin (NYSE: CYBN) is poised to make huge moves in 2022.
|
As you’re about to see, major institutions and big money are lining up behind psychedelics as a treatment for a host of mental illnesses…
…And Cybin has a three-pillared approach that promises to put it near the head of the biotech pack.
|
A New Day For Magic Mushrooms
And Other Psychedelics
|
The excesses of 1960s counterculture landed psylocibin, the active ingredient in “magic mushrooms,” on the FDA’s Schedule 1 list along with LSD and other hallucinogens in the early 1970s.
That ban stopped promising research on controlled uses of psychedelics in its tracks.
Today, with society’s changing views toward medical and recreational marijuana, institutions have renewed their research efforts on psychedelics as a possible treatment for a variety of mental health issues.
Funds are now flowing toward psychedelics research at renowned medical institutions, including…
|
• Johns Hopkins University
• Yale School of Medicine
• New York’s Mt. Sinai School of Medicine
• London’s Imperial College of Science, Technology and Medicine
• University of California, San Diego
|
And the results have been promising, with clinically administered doses of psychedelics showing real promise at treating depression, PTSD, OCD, chronic pain and more.
Save
Not A Subscriber Yet?
Get Golden Opportunities For Free
Subscribe to our Golden Opportunities e-letter to receive timely market
updates from the Gold Newsletter research team, plus video
presentations by expert speakers from the New Orleans Conference
— and the Investor’s Guide to Gold and Silver — all at no cost!
CLICK HERE to start your subscription.
|
The Big Money Is Lining Up
Behind Psychedelics
|
The imprimatur of those prestigious medical institutions has attracted big money to the psychedelics space.
|
• Billionaire investor Peter Thiel, the co-founder of PayPal, has invested more than $12 million in a variety of psychedelic stocks.
• Multi-millionaire and “Shark Tank” co-star Kevin O’Leary is on record as being a “big investor” in this sector.
• And then there’s the money behind Cybin itself, which has already raised C$120 million from a group of institutional investors.
|
That’s money that Cybin can use to advance its drug candidates through the FDA approval process and stay on the leading edge of research on new candidates.
|
Investment Research Firms Are Predicting
Dazzling Returns For CYBN
|
Investment research firms are starting to pick up on the Cybin story.
The most recent example came from New York Investment bank Oppenheimer — which is forecasting that CYBN could more than triple to $7/share in the next 12 to 18 months.
Roth Capital Partners sees an even higher valuation for CYBN, conservatively estimating it can hit $10/share in the next year.
Those kinds of estimates make sense, given that Canaccord Genuity is predicting the psychedelic space could become a $100 billion a year business, and depression medications alone make Big Pharma $60 billion annually.
|
A Business Model With Three Powerful Pillars
|
Cybin’s approach to the psychedelic space rests on three pillars:
Pillar #1: Build a novel drug discovery platform
To be patentable, drugs need to be created that are “active pharmaceutical ingredients” or “APIs,” Cybin is in the process of developing multiple APIs by modifying the molecules in psilocybin, deuterated tryptamine and other psychedelics to make patentable and saleable forms of psychedelic medications.
Pillar #2: Develop proprietary drug delivery and formulation approaches
Cybin is hard at work on new delivery methods for its investigational drugs that can maximize bioavailability. One of those that may soon be patented is an intra-oral film that would be absorbed in a patient’s mouth, bypassing the inherently inefficient digestive system as a means of delivering a drug.
Pillar #3: Produce a novel treatment regimen
Cybin is also building a software-based platform designed to gather clinical research data from psychedelic treatment to help the company refine its formulations and to create improved drugs in the future.
| |
As you can tell from the forecasts of Oppenheimer and Roth Capital, this plan of attack has astute investors excited about Cybin’s ability to become one of the sector’s big winners.
With a drug in Phase II clinical trials for depression and another set to enter Phase I testing for alcohol use disorder, Cybin has the money and the plan to deliver outsized returns for early investors.
|
In spite of the recent institutional coverage, Cybin is still flying below the radar in terms of its valuation…for now.
| |
But 2022 looks bright for the company and the psychedelic space as a whole, making now a perfect time to take a closer look at Cybin.
| | | | |
© Golden Opportunities, 2009 - 2022
| Advertisements included in this issue do not constitute endorsements from us of any stock or investment recommendation made by our advertisers.
Warnings and Disclaimers: As you know, every investment entails risk. Golden Opportunities hasn’t researched and cannot assess the suitability of any investments mentioned or advertised by our advertisers. We recommend you conduct your own due diligence and consult with your financial adviser before entering into any type of financial investment. This profile should be viewed as a paid advertisement. The publisher and staff of this publication may hold positions in the securities of companies discussed or recommended. The information contained herein has been received from sources which the publisher deems reliable. However, the publisher cannot guarantee that such information is complete and true in all respects. The advertiser provided a review of the factual content of this advertisement at the time of publication. The publisher is not a registered investment adviser and does not purport to offer personalized investment related advice; the publisher does not determine the suitability of advice and recommendations contained herein for any reader. Each person must separately determine whether such advice and recommendations are suitable and whether they fit within such person’s goals and portfolio. The advertiser featured in this edition of Golden Opportunities has paid the publisher for the costs and compensation related to the authorship, overhead, design and distributing this online edition, in the amount of $7,500. The publisher may receive revenue, the amount of which cannot be predetermined, from sales resulting from any accompanying offer. Authors of articles contained herein may have been compensated for their services in preparing such articles.
Golden Opportunities
Jefferson Companies
111 Veterans Memorial Blvd. Suite 1555
New Orleans, LA 70005
1-800-648-8411
| | | |
.png)
